查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1663312

神经栓塞设备 - 市场洞察、竞争格局、2032年市场预测

Neurovascular Embolization Devices - Market Insights, Competitive Landscape, and Market Forecast - 2032
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

2024年全球神经血管栓塞装置市场规模价值为 13.4766亿美元，预计到2032年将达到 18.9084亿美元，预测期内（2025-2032年）的年复合成长率为 4.40%。动脉瘤、严重头部创伤、久坐的生活方式和缺血性中风等神经血管疾病的盛行率不断上升，大大推动了全球神经血管栓塞设备市场的发展。这些疾病通常需要精确、微创治疗，而栓塞装置非常重要。此外，高血压是神经血管疾病的主要危险因素，全球高血压发生率上升，导致脑出血和动脉瘤发病率高，进一步增加了对有效栓塞解决方案的需求。

主要市场参与者持续的产品开发活动促成了先进、高效的栓塞设备的推出，改善了患者的治疗效果和手术成功率。设备设计、生物相容性和输送机制的创新提高治疗的精确度和安全性，并扩大其在医疗保健提供者中的应用。

大致上，这些因素预计将在2025-2032年的预测期内推动全球神经血管栓塞设备市场显着成长。

神经血管栓塞装置的市场动态：

根据Global Burden of Disease（2024），2021年神经系统疾病影响了全球约 43%的人口，约 34亿人。紧张型头痛最常见，影响约20亿人，其次是偏头痛，影响约 11亿人。此外，自 1990年以来，全球糖尿病神经病变盛行率增加了两倍多，到2021年达到 2.06亿人。慢性紧张型头痛常影响血管，而糖尿病神经病变可造成血管损伤，增加动脉瘤和动静脉畸形（AVM）等神经血管疾病的风险。随着这些神经系统疾病的发生率上升，对微创治疗的需求也日益成长，以降低中风和其他血管併发症的风险。用于阻断异常血流和封堵动脉瘤的神经血管栓塞装置在治疗这些疾病方面发挥越来越重要的作用，推动了全球市场的成长。

根据这些趋势，英国心臟基金会（2024）报告指出，全世界约有 5,600万名女性和 4,500万名男性是中风倖存者。中风通常是由脑血栓、动脉瘤或脑血管异常形成引起的，需要迅速介入以恢復血流并防止出血。神经血管栓塞装置，包括线圈、支架和液体栓塞剂，对于治疗这些疾病非常重要，它可以阻塞动脉瘤，防止血管破裂，并阻止异常血流流向受损的脑组织，进一步推动市场扩张。

疾病盛行率的上升以及产品开发活动的增加预计将推动市场成长。例如，2021年4月，Medtronic公司获得FDA批准，生产带有Shield Technology（TM）的Pipeline（TM）Flex神经血管栓塞装置，该装置目的是减少血栓形成并降低血流改道手术期间血栓形成的风险。

在这些成长动力中，某些挑战也可能阻碍市场的发展。与栓塞相关的併发症，例如微导管、微导丝和线圈造成的动脉瘤穿孔，会带来手术风险。此外，严格的监管审批流程可能会延迟产品推出并抑制市场成长。

北美预计将主导整个神经栓塞设备市场

预计到2024年北美将占据全球神经血管栓塞设备市场的最大占有率。该地区市场的成长主要得益于动脉瘤、高血压和出血等神经血管疾病的高发性、产品开发活动的增加以及政府的支持措施。预计这些因素将在预测期内（2025-2032年）对市场扩张做出重大贡献。

本报告研究了全球神经栓塞设备市场，提供了市场规模和预测、过去三年的产品/技术发展、市场主要参与者和可用机会的资讯。

目录

第1章 神经血管栓塞设备市场报告简介

第2章 神经栓塞设备市场执行摘要

  • 市场概况

第3章 竞争格局

第4章 监理分析

  • 美国
  • 欧洲
  • 日本
  • 中国

第5章 神经血管栓塞设备市场的关键因素分析

  • 神经血管栓塞设备市场驱动因素
  • 神经栓塞装置市场的限制与挑战
  • 神经血管栓塞装置的市场机会

第6章 神经血管栓塞设备市场的波特五力分析

第7章 神经栓塞设备市场评估

  • 依产品类型
    • 栓塞线圈
    • 神经血管线圈辅助装置
    • 液体栓塞系统
    • 导流支架
    • 囊内血流扰乱器
    • 其他
  • 依最终用户
    • 医院
    • 门诊手术中心
  • 区域
    • 北美洲
    • 欧洲
    • 亚太地区
    • 其他地区

第8章 神经血管栓塞设备市场中的公司与产品概况

  • Medtronic PLC
  • Stryker
  • MicroVention, Inc. (Terumo Corporation)
  • Johnson & Johnson Services, Inc.
  • Penumbra, Inc.
  • B. Braun Melsungen AG
  • Acandis GmbH
  • Wallaby Medical.
  • Shape Memory Medical Inc.
  • Zylox-Tonbridge Medical Technology Co., Ltd.
  • Spartan Micro, Inc.
  • KANEKA CORPORATION
  • Lepu Medical Technology (Beijing) Co., Ltd.
  • Meril Life Sciences Pvt. Ltd.
  • Boston Scientific Corporation
  • phenox GmbH
  • Merit Medical Systems.
  • Perflow Medical Ltd.
  • MicroPort Scientific Corporation.
  • Cerus Endovascular

第9章 KOL 视角

第10章 专案方法

第11章 关于 DelveInsight

第12章 免责声明、联络我们

Product Code: DIMDCL0477

Neurovascular Embolization Device Market by Product Type (Embolization Coils, Neurovascular Coil Assist Devices [Coil Assist Stents and Coil Assist Balloons], Liquid Embolization Systems, Flow Diversion Stents, Intrasaccular Flow Disruptor, and Others), By End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the growing prevalence of neurovascular disorders, increase in prevalence of hypertension across the globe, and increase in product development activities by the key market players across the globe.

The neurovascular embolization devices market was valued at USD 1,347.66 million in 2024, growing at a CAGR of 4.40% during the forecast period from 2025 to 2032, to reach USD 1,890.84 million by 2032. The rising prevalence of neurovascular disorders such as aneurysms, severe head injuries, sedentary lifestyles, and ischemic strokes is significantly driving the global market for neurovascular embolization devices. These conditions often require precise, minimally invasive treatments, for which embolization devices are critical. Additionally, the global increase in hypertension a major risk factor for neurovascular diseases has led to a higher incidence of brain hemorrhages and aneurysms, further fueling demand for effective embolization solutions.

Ongoing product development efforts by key market players are introducing advanced and efficient embolization devices, improving patient outcomes and procedural success rates. Innovations in device design, biocompatibility, and delivery mechanisms are enhancing treatment precision and safety, thereby expanding adoption among healthcare providers.

Collectively, these factors are expected to drive substantial growth in the global neurovascular embolization devices market during the forecast period from 2025 to 2032.

Neurovascular Embolization Devices Market Dynamics:

According to the Global Burden of Disease (2024), neurological conditions affected approximately 43% of the global population in 2021, impacting around 3.4 billion individuals. Among these, tension-type headaches were the most prevalent, with an estimated 2 billion cases, followed by migraines affecting approximately 1.1 billion people. Additionally, the global prevalence of diabetic neuropathy has more than tripled since 1990, reaching 206 million cases in 2021. Chronic tension headaches often have vascular implications, while diabetic neuropathy can lead to vascular damage, increasing the risk of neurovascular conditions such as aneurysms and arteriovenous malformations (AVMs). As the incidence of these neurological disorders rises, the demand for minimally invasive treatments to mitigate the risks of stroke and other vascular complications is growing. Neurovascular embolization devices used to block abnormal blood flow or seal aneurysms play an increasingly vital role in addressing these conditions, thereby driving global market growth.

Complementing these trends, the British Heart Foundation (2024) reported that approximately 56 million women and 45 million men worldwide were stroke survivors. Strokes, often caused by blood clots, aneurysms, or abnormal blood vessel formations in the brain, require prompt intervention to restore blood flow and prevent hemorrhagic events. Neurovascular embolization devices including coils, stents, and liquid embolic agents are essential in treating these conditions by sealing aneurysms, preventing vessel ruptures, and blocking abnormal blood flow to damaged brain tissue, further propelling market expansion.

In addition to rising disease prevalence, increasing product development activities are expected to bolster market growth. For instance, in April 2021, Medtronic plc received FDA approval for its Pipeline(TM) Flex Neurovascular Embolization Device with Shield Technology(TM), designed to reduce thrombogenicity and lower the risk of clot formation during flow diversion therapy.

Despite these growth drivers, certain challenges may impede market progress. Complications associated with embolization procedures such as aneurysmal perforations caused by micro catheters, micro-guidewires, or coils pose procedural risks. Moreover, stringent regulatory approval processes can delay product launches, potentially restraining market growth.

Neurovascular Embolization Devices Market Segment Analysis:

Neurovascular Embolization Device Market by Product Type (Embolization Coils, Neurovascular Coil Assist Devices [Coil Assist Stents and Coil Assist Balloons], Liquid Embolization Systems, Flow Diversion Stents, Intrasaccular Flow Disruptor, and Others), By End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of the global neurovascular embolization devices market, embolization coils are projected to hold the largest share in 2024. These coils, typically made from platinum or other biocompatible materials, are inserted into aneurysms to promote clot formation, effectively sealing the aneurysm and preventing rupture. As a minimally invasive alternative to open surgery, embolization coils offer patients faster recovery times and lower complication risks, making them a preferred choice in neurovascular procedures.

Technological advancements such as improved coil flexibility, enhanced precision, and better radiopacity have further driven their adoption in both emergency and elective neurovascular treatments. These innovations enable physicians to navigate complex vascular anatomies more efficiently, improving procedural success rates and patient outcomes.

Moreover, increased funding for the development and commercialization of neurovascular embolization coils is contributing to market growth. For example, in July 2021, Zylox-Tonbridge Medical Technology Co., Ltd. raised USD 329 million to support the development of its core neurovascular products, including embolization coils and micro catheters for coiling procedures.

Collectively, these factors are expected to generate significant revenue for the embolization coil segment, driving the overall growth of the global neurovascular embolization devices market during the forecast period.

North America is expected to dominate the overall neurovascular embolization devices market:

North America is projected to hold the largest share of the global neurovascular embolization devices market in 2024. The region's market growth is primarily driven by the high prevalence of neurovascular disorders such as aneurysms, hypertension, and hemorrhages coupled with increasing product development activities and supportive government initiatives. These factors are expected to significantly contribute to market expansion during the forecast period (2025 to 2032).

According to the Brain Aneurysm Foundation (2024), an estimated 6.8 million people in the United States approximately 1 in 50 individuals were living with an unruptured brain aneurysm in 2021. The annual rupture rate ranged from 8 to 10 per 100,000 people, with approximately 30,000 aneurysm ruptures occurring each year, translating to one rupture every 18 minutes. This growing diagnosis rate of both ruptured and unruptured aneurysms underscores the need for advanced, minimally invasive treatment solutions. Neurovascular embolization devices including coils, flow diverters, and stents are pivotal in preventing aneurysm ruptures and managing bleeding, offering safer alternatives to traditional open surgeries.

Similarly, the prevalence of strokes further escalates market demand. As per the Centers for Disease Control and Prevention (CDC, 2024), a stroke occurs every 40 seconds in the United States, affecting over 795,000 individuals annually. Of these, approximately 610,000 are first-time strokes, while around 185,000 occur in individuals with a prior stroke. Ischemic strokes caused by blocked blood flow to the brain account for about 87% of these cases. With hypertension being a leading risk factor for both ischemic and hemorrhagic strokes, the growing hypertensive population elevates the incidence of aneurysms, arteriovenous malformations (AVMs), and other neurovascular conditions. Consequently, this drives the need for neurovascular embolization devices to effectively manage and treat these conditions.

Government initiatives aimed at improving brain aneurysm research are further propelling market growth. For example, in March 2021, during the 117th Congressional Session, the U.S. government allocated USD 10 million annually from 2022 to 2030 to support comprehensive research on unruptured intracranial aneurysms, with funds available through September 30, 2029. Such funding is instrumental in fostering technological advancements and improving patient care.

In conclusion, the combination of a high disease burden, technological advancements, supportive policy measures, and increased public awareness is expected to bolster the North American neurovascular embolization devices market during the forecast period.

Neurovascular Embolization Devices Market Key Players:

Some of the key market players operating in the neurovascular embolization devices market include Medtronic PLC, Stryker, MicroVention, Inc. (Terumo Corporation), Johnson & Johnson Services, Inc., Penumbra, Inc., B. Braun Melsungen AG, Acandis GmbH, Wallaby Medical., Shape Memory Medical Inc., Zylox-Tonbridge Medical Technology Co., Ltd., Spartan Micro, Inc., KANEKA CORPORATION, Lepu Medical Technology(Beijing)Co., Ltd., Meril Life Sciences Pvt. Ltd., Boston Scientific Corporation, phenox GmbH, Merit Medical Systems., Perflow Medical Ltd., MicroPort Scientific Corporation., Cerus Endovascular, and others.

Recent Developmental Activities in the Neurovascular Embolization Devices Market:

  • In July 2024, MicroVention, Inc., a neurovascular company and subsidiary of Terumo Corporation, announced the publication of the CLEVER trial results. This multicenter, prospective study involved 163 patients across 17 European centers. Investigators assessed the safety and effectiveness of MicroVention's Woven EndoBridge (WEB) 17 system for treating ruptured and unruptured aneurysms. The WEB 17 is the company's newest and smallest aneurysm embolization system.

Key Takeaways from the Neurovascular Embolization Devices Market Report Study:

  • Market size analysis for current neurovascular embolization devices size (2024), and market forecast for 8 years (2025 to 2032)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
  • Key companies dominating the neurovascular embolization devices market.
  • Various opportunities available for the other competitors in the neurovascular embolization devices market space.
  • What are the top-performing segments in 2024? How these segments will perform in 2032?
  • Which are the top-performing regions and countries in the current neurovascular embolization devices market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for neurovascular embolization devices market growth in the coming future?

Target Audience Who Can be Benefited from this Neurovascular Embolization Devices Market Report Study:

  • Neurovascular embolization device providers
  • Research organizations and consulting companies
  • Neurovascular embolization devices -related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in neurovascular embolization devices
  • Various end-users who want to know more about the neurovascular embolization devices market and the latest technological developments in the neurovascular embolization devices market.

Frequently Asked Questions for the Neurovascular Embolization Devices Market:

1. What are neurovascular embolization devices?

  • A neurovascular embolization device is an intravascular implant intended to permanently occlude blood flow to cerebral aneurysms and cerebral arteriovenous malformations.

2. What is the market for neurovascular embolization devices?

  • The neurovascular embolization devices market was valued at USD 1,3477.66 million in 2024, growing at a CAGR of 4.40% during the forecast period from 2025 to 2032, to reach USD 1,890.84 million by 2032.

3. What are the drivers for the neurovascular embolization devices market?

  • The growing prevalence of neurovascular disorders, such as aneurysms, severe head injuries, sedentary lifestyles, and ischemic strokes, is significantly boosting the market for neurovascular embolization devices. Additionally, the global rise in hypertension, a major risk factor for neurovascular diseases, has increased the number of patients susceptible to conditions like brain hemorrhages and aneurysms, thus driving the demand for effective embolization devices. Furthermore, increased product development activities by key market players across the globe are introducing more advanced and efficient embolization solutions, improving outcomes for patients and enhancing procedural success. Together, these factors are expanding the global market for neurovascular embolization devices.

4. Who are the key players operating in the neurovascular embolization devices market?

  • Some of the key market players operating in the neurovascular embolization devices market include Medtronic PLC, Stryker, MicroVention, Inc. (Terumo Corporation), Johnson & Johnson Services, Inc., Penumbra, Inc., B. Braun Melsungen AG, Acandis GmbH, Wallaby Medical., Shape Memory Medical Inc., Zylox-Tonbridge Medical Technology Co., Ltd., Spartan Micro, Inc., KANEKA CORPORATION, Lepu Medical Technology(Beijing)Co., Ltd., Meril Life Sciences Pvt. Ltd., Boston Scientific Corporation, phenox GmbH, Merit Medical Systems., Perflow Medical Ltd., MicroPort Scientific Corporation., Cerus Endovascular, and others.

5. Which region has the highest share in the neurovascular embolization devices market?

  • Among all the regions, North America is expected to hold the largest share of the global neurovascular embolization devices market in 2024. The growing prevalence of neurovascular disorders, such as aneurysms, hypertension, hemorrhages, and others is expected to boost the market across the region. Additionally, recent product developmental activities and rising government initiatives are expected to aid in the growth of the North American neurovascular embolization devices market during the forecast period from 2025 to 2032.

Table of Contents

1. Neurovascular Embolization Devices Market Report Introduction

  • 1.1. Scope of the Study
  • 1.2. Market Segmentation
  • 1.3. Market Assumption

2. Neurovascular Embolization Devices Market Executive Summary

  • 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

  • 4.1. The United States
  • 4.2. Europe
  • 4.3. Japan
  • 4.4. China

5. Neurovascular Embolization Devices Market Key Factors Analysis

  • 5.1. Neurovascular Embolization Devices Market Drivers
    • 5.1.1. Growing prevalence of neurovascular disorders such as brain aneurysm, hemorrhage, and others due to severe head injuries, sedentary lifestyle, others
    • 5.1.2. Increase in prevalence of hypertension across the globe
    • 5.1.3. Increase in product development activities by key market players across the globe
  • 5.2. Neurovascular Embolization Devices Market Restraints and Challenges
    • 5.2.1. Complications associated with embolization coils
    • 5.2.2. Stringent regulatory approvals
  • 5.3. Neurovascular Embolization Devices Market Opportunities
    • 5.3.1. Continuous innovations in embolization technology, including more precise, flexible, and safer devices

6. Neurovascular Embolization Devices Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Neurovascular Embolization Devices Market Assessment

  • 7.1. By Product Type
    • 7.1.1. Embolization Coils
    • 7.1.2. Neurovascular Coil Assist Devices
      • 7.1.2.1. Coil Assist Stents
      • 7.1.2.2. Coil Assist Balloons
    • 7.1.3. Liquid Embolization Systems
    • 7.1.4. Flow Diversion Stents
    • 7.1.5. Intrasaccular Flow Disruptor
    • 7.1.6. Others
  • 7.2. By End-User
    • 7.2.1. Hospitals
    • 7.2.2. Ambulatory Surgical Centers
    • 7.2.3. Others
  • 7.3. By Geography
    • 7.3.1. North America
      • 7.3.1.1. United States Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
      • 7.3.1.2. Canada Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
      • 7.3.1.3. Mexico Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
    • 7.3.2. Europe
      • 7.3.2.1. France Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
      • 7.3.2.2. Germany Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
      • 7.3.2.3. United Kingdom Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
      • 7.3.2.4. Italy Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
      • 7.3.2.5. Spain Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
      • 7.3.2.6. Rest of Europe Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
    • 7.3.3. Asia-Pacific
      • 7.3.3.1. China Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
      • 7.3.3.2. Japan Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
      • 7.3.3.3. India Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
      • 7.3.3.4. Australia Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
      • 7.3.3.5. South Korea Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
      • 7.3.3.6. Rest of Asia-Pacific Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
    • 7.3.4. Rest of the World (RoW)
      • 7.3.4.1. Middle East Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
      • 7.3.4.2. Africa Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
      • 7.3.4.3. South America Neurovascular Embolization Devices Market Size in USD Million (2022-2032)

8. Neurovascular Embolization Devices Market Company and Product Profiles

  • 8.1. Medtronic PLC
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. Stryker
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. MicroVention, Inc. (Terumo Corporation)
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. Johnson & Johnson Services, Inc.
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. Penumbra, Inc.
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. B. Braun Melsungen AG
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. Acandis GmbH
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. Wallaby Medical.
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. Shape Memory Medical Inc.
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. Zylox-Tonbridge Medical Technology Co., Ltd.
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. Spartan Micro, Inc.
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. KANEKA CORPORATION
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. Lepu Medical Technology (Beijing)Co., Ltd.
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. Meril Life Sciences Pvt. Ltd.
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. Boston Scientific Corporation
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy
  • 8.16. phenox GmbH
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4. Product Listing
    • 8.16.5. Entropy
  • 8.17. Merit Medical Systems.
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4. Product Listing
    • 8.17.5. Entropy
  • 8.18. Perflow Medical Ltd.
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4. Product Listing
    • 8.18.5. Entropy
  • 8.19. MicroPort Scientific Corporation.
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4. Product Listing
    • 8.19.5. Entropy
  • 8.20. Cerus Endovascular
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4. Product Listing
    • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: Neurovascular Embolization Devices Market in Global (2022-2032)
  • Table 3: Neurovascular Embolization Devices Market in Global by Product Type (2022-2032)
  • Table 4: Neurovascular Embolization Devices Market in Global by End-User (2022-2032)
  • Table 5: Neurovascular Embolization Devices Market in Global by Geography (2022-2032)
  • Table 6: Neurovascular Embolization Devices Market in North America (2022-2032)
  • Table 7: Neurovascular Embolization Devices Market in the United States (2022-2032)
  • Table 8: Neurovascular Embolization Devices Market in Canada (2022-2032)
  • Table 9: Neurovascular Embolization Devices Market in Mexico (2022-2032)
  • Table 10: Neurovascular Embolization Devices Market in Europe (2022-2032)
  • Table 11: Neurovascular Embolization Devices Market in France (2022-2032)
  • Table 12: Neurovascular Embolization Devices Market in Germany (2022-2032)
  • Table 13: Neurovascular Embolization Devices Market in United Kingdom (2022-2032)
  • Table 14: Neurovascular Embolization Devices Market in Italy (2022-2032)
  • Table 15: Neurovascular Embolization Devices Market in Spain (2022-2032)
  • Table 16: Neurovascular Embolization Devices Market in the Rest of Europe (2022-2032)
  • Table 17: Neurovascular Embolization Devices Market in Asia-Pacific (2022-2032)
  • Table 18: Neurovascular Embolization Devices Market in China (2022-2032)
  • Table 19: Neurovascular Embolization Devices Market in Japan (2022-2032)
  • Table 20: Neurovascular Embolization Devices Market in India (2022-2032)
  • Table 21: Neurovascular Embolization Devices Market in Australia (2022-2032)
  • Table 22: Neurovascular Embolization Devices Market in South Korea (2022-2032)
  • Table 23: Neurovascular Embolization Devices Market in Rest of Asia-Pacific (2022-2032)
  • Table 24: Neurovascular Embolization Devices Market in the Rest of the World (2022-2032)
  • Table 25: Neurovascular Embolization Devices Market in the Middle East (2022-2032)
  • Table 26: Neurovascular Embolization Devices Market in Africa (2022-2032)
  • Table 27: Neurovascular Embolization Devices Market in South America (2022-2032)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: Neurovascular Embolization Devices Market in Global (2022-2032)
  • Figure 3: Neurovascular Embolization Devices Market in Global by Product Type (2022-2032)
  • Figure 4: Neurovascular Embolization Devices Market in Global by End-User (2022-2032)
  • Figure 5: Neurovascular Embolization Devices Market in Global by Geography (2022-2032)
  • Figure 6: Neurovascular Embolization Devices Market in North America (2022-2032)
  • Figure 7: Neurovascular Embolization Devices Market in the United States (2022-2032)
  • Figure 8: Neurovascular Embolization Devices Market in Canada (2022-2032)
  • Figure 9: Neurovascular Embolization Devices Market in Mexico (2022-2032)
  • Figure 10: Neurovascular Embolization Devices Market in Europe (2022-2032)
  • Figure 11: Neurovascular Embolization Devices Market in France (2022-2032)
  • Figure 12: Neurovascular Embolization Devices Market in Germany (2022-2032)
  • Figure 13: Neurovascular Embolization Devices Market in United Kingdom (2022-2032)
  • Figure 14: Neurovascular Embolization Devices Market in Italy (2022-2032)
  • Figure 15: Neurovascular Embolization Devices Market in Spain (2022-2032)
  • Figure 16: Neurovascular Embolization Devices Market in the Rest of Europe (2022-2032)
  • Figure 17: Neurovascular Embolization Devices Market in Asia-Pacific (2022-2032)
  • Figure 18: Neurovascular Embolization Devices Market in China (2022-2032)
  • Figure 19: Neurovascular Embolization Devices Market in Japan (2022-2032)
  • Figure 20: Neurovascular Embolization Devices Market in India (2022-2032)
  • Figure 21: Neurovascular Embolization Devices Market in Australia (2022-2032)
  • Figure 22: Neurovascular Embolization Devices Market in South Korea (2022-2032)
  • Figure 23: Neurovascular Embolization Devices Market in Rest of Asia-Pacific (2022-2032)
  • Figure 24: Neurovascular Embolization Devices Market in the Rest of the World (2022-2032)
  • Figure 25: Neurovascular Embolization Devices Market in the Middle East (2022-2032)
  • Figure 26: Neurovascular Embolization Devices Market in Africa (2022-2032)
  • Figure 27: Neurovascular Embolization Devices Market in South America (2022-2032)
  • Figure 28: Market Drivers
  • Figure 29: Market Barriers
  • Figure 30: Market Opportunities
  • Figure 31: PORTER'S Five Force Analysis